Develop breakthrough noninvasive tests for earlier cancer diagnosis based on disruptive morpho-molecular rare cells technology.

The ISET^© technology is able to extract a single Circulating Tumor Cell (CTC) from 10 ml of blood (thus mixed with approx. 100 M. of leucocytes and 50 B. of erythrocytes) keeping CTCs intact and ready for  morpho-molecular analyses, providing unparalleled sensitivity and specificity.

ISET^© also extracts from blood, without loss, circulating giant cells and tumor cell clusters (micro-emboli).

Rarecells partners with the most prestigious US academic institutions to bring to the market the ISET^© non-invasive tests, contributing to the eradication of cancer.